Effects of pioglitazone on TGFbeta1 expression in ischemia/reperfusion injury myocardium of rats.
- Author:
Hao WANG
1
;
Ping YE
;
Yang LI
;
Zong-Bin LI
;
Lin WANG
Author Information
- Publication Type:Journal Article
- MeSH: Anilides; pharmacology; Animals; Apoptosis; Male; Myocardial Reperfusion Injury; metabolism; Myocardium; metabolism; PPAR gamma; antagonists & inhibitors; Rats; Rats, Sprague-Dawley; Thiazolidinediones; pharmacology; Transforming Growth Factor beta1; metabolism
- From: Chinese Journal of Applied Physiology 2013;29(1):1-4
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo investigate the effects of pioglitazone on transforming growth factor beta1 (TGFbeta1) expression in ischemia/reperfusion injury myocardium of rats.
METHODSThirty SD rats were randomly divided into five groups (n = 6): ischemia/reperfusion group, pioglitazone 5 mg/(kg x d) group, pioglitazone 10 mg/(kg x d) group, pioglitazone 20 mg/(kg x d) group and pioglitazone 20 mg/(kg x d) + peroxisome proliferator-activated receptor gamma (PPARgamma) specific antagonist GW9662 group. Left anterior descending coronary artery of rats were ligated for 30 min and reperfused for 120 min to establish the model of ischemia/reperfusion in vivo. RT-PCR was performed to detect the expression of TGFbeta1 mRNA. Western blot was performed to detect the expression of TGFbeta1 protein.
RESULTSMyocardial apoptosis was significantly suppressed by pioglitazone. Pioglitazone upregulated TGFPbeta1 expression both in mRNA and protein level. GW9662 reversed the inhibition of myocardial apoptosis and the upregulation of TGFbeta1 expression by pioglitazone.
CONCLUSIONPioglitazone can inhibit the myocardial apoptosis induced by ischemia/reperfusion. Pioglitazone may protect the myocardium from ischemia/reperfusion via upregulation of TGFbeta1. This protection may be mediated by PPARgamma.
